The $98.9 million investment is going to 59 navigator organizations to help consumers find coverage during the 2023 open enrollment period. One recipient said the funding will be especially helpful as the end of the Covid-19 public health emergency nears, when a projected 15 million people will lose coverage.
Decentralized clinical trial approaches helped the pharma industry navigate through Covid-19. Now it is becoming increasingly clear that there's a need for a hybrid approach to decentralized clinical trials that considers the perspectives of patients and the impact to clinical trial sites.
We personally invite you to join us at Pegasus Park in Dallas on Wednesday, September 28 to partake in thought provoking panel discussions. Plus, this event offers an 6:1 ratio of attendees to investors for those seeking funding and a desire to network.
Don't miss this valuable opportunity to network and connect:
By Frank Vinluan Tuesday, August 30, 2022 10:25 PM
Amgen said its drug Lumakras met the main goal of a Phase 3 study in non-small cell lung cancer driven by a particular genetic mutation. The pharmaceutical giant offered no specifics, but the results set the stage for an interesting regulatory race with a rival drug from Mirati Therapeutics
Avenda Health, an AI company focused on personalized prostate cancer care, recently closed a $10 million Series B funding round. The company's platform seeks to personalize treatment to the patient and their specific case to preserve quality of life and prevent cancer recurrence.
Health data company CuriMeta launched on Tuesday and announced the close of a $6 million seed funding round led by its two institutional partners, BJC HealthCare and the Washington University School of Medicine. The company's mission is to leverage its two institutional partners' deep data resources to create more useful data that enables quicker discoveries of new diagnostics and medical interventions.
By Marissa Plescia Tuesday, August 30, 2022 2:16 PM
The four companies are Alma, Headway, NOCD and Ophelia. Alma and Headway will help Empire expand its mental health provider network, while NOCD and Ophelia will address specific conditions: obsessive-compulsive disorder and opioid use disorder, respectively.
Decreased spending power compounds the impact of social risk particularly by surfacing other associated deficiencies in areas such as health literacy, digital access and social isolation.
Neurocrine Biosciences is acquiring Diurnal Group, a U.K-based biotech that has commercialized two endocrine disorder drugs. Neurocrine's top-selling product is a blockbuster drug for an involuntary muscle movement disorder.
By Stephanie Baum Tuesday, August 30, 2022 12:33 PM
In a recent interview, Jennifer Cubino, COO of BC Platforms, discussed regulatory differences between the U.S., the European Union and other countries amid ongoing efforts to encourage patients who want to share their data.
In the near future, healthcare organizations will likely need to document how they collect health equity data, screen patients for social determinants of health, and address disparities in care.
Today, the pharmaceutical industry is undergoing a rapid and dynamic transformation. Successful contract management plays an instrumental role in navigating this landscape.
No comments